Table 1.

Selected pulmonary hepatoid carcinomas in the literature.

Case	Tumor site	Pathology review	Size (cm)	Serum AFP (ng/mL)	Stage	Prognosis	Reference (year)
1 (67/M)	LUL	Ad	8.0	160,000	IV	16 mo, D	Yasunami et al. [4] (1981)
2 (66/M)	RLL	Large	11.0	88,000	IV	6 mo, D	Yokoyama et al. [4] (1981)
3 (40/M)	RUL	Ad	9.0	3090	IV	14 mo, D	Miyake et al. [4] (1986)
4 (55/M)	RUL	Ad	5.0	2123	IIIA	4 d, D	Miyake et al. [4] (1986)
5 (73/M)	LUL	Ad	6.0	1039	IV	19 mo, D	Miyake et al. [4] (1987)
6 (36/M)	LUL	Ad	10.0	11,600	IIIB	7 mo, D	Arnould et al. [9] (1997)
7 (63/M)	RUL	Large	8.0	14,000	IV	11 mo, D	Nasu et al. [2] (1997)
8 (82/M)	LLL	Large	3.5	Normal	IB	7 y, A	Carlinfante et al. [1] (2000)
9 (55/M)	RUL	Ad	6.0	89 a	IIA	30 mo, A	Hayashi et al. [10] (2002)
10 (71/M)	RLL	Large	10.5	9826	IIIA	12 mo, D	Hiroshima et al. [3] (2002)
11 (50/M)	RUL	Large b	6.0	Normal	IIB	45 mo, A	Wu et al. [11] (2007)
12 (64/M)	RUL	Large	7.5	673	IIB	NA	Kishimoto et al. [7] (2008)
13 (52/M)	LUL	Ad	12	5000	NA	2 mo, A	Mokrim et al. [12] (2011)
14 (66/M)	RUL	Large	7.4	8868	IIB	4 y, A	Present case

A = alive; ad = adenocarcinoma; D = died of disease; large = larger cell carcinoma; LLL = left lower lobe; LUL = left upper lobe; mo = months; NA = data not available; RLL = right lower lobe; RUL = right upper lobe; y = years.

^aSerum level after surgery.

^bNo tubular or papillary adenocarcinomatous component described.